A Phase 3 interventional study of Ixekizumab and Placebo in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 125 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-17.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 3rd largest by enrollment, is one of 3 that started in 2015, is one of 11 in phase 3, and was the 8th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,257 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 5th largest by enrollment, is one of 3 that started in 2015, is one of 15 in phase 3, and was the 12th registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
The purpose of this study is to evaluate both the safety and efficacy of ixekizumab dosing regimens. There are 3 study periods: Screening Period, Blinded Treatment Dosing Period, and Post-Treatment Follow-Up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52. Placebo administered SQ, Q2W to maintain blind.
Drug: Ixekizumab · Drug: Placebo
160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.
Drug: Ixekizumab · Drug: Placebo
160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
Drug: Ixekizumab · Drug: Placebo
160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52. Placebo administered SQ, Q2W to maintain blind.
Drug: Ixekizumab · Drug: Placebo
160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.
Drug: Ixekizumab · Drug: Placebo
160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
Drug: Ixekizumab · Drug: Placebo
Administered SQ
Also known as: LY2439821
Administered SQ
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1)
The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.
Time frame: Week 52
Percentage of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75)
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants who did not meet the clinical response criteria or had missing data at Week52 were considered non-responders for NRI analysis.
Time frame: Week 52
Percentage of Participants Achieving sPGA (0)
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.
Time frame: Week 52
Percentage of Participants Achieving PASI 90
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Week 52
Percentage of Participants Achieving PASI 100
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Week 52
Change From Baseline in PASI
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares mean (LSmean) was calculated using Mixed-Effects Model of Repeated Measures (MMRM) analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 52
Percent Improvement in PASI
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares mean (LSmean) was calculated using Mixed-Effects Model of Repeated Measures (MMRM) analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 52
Mean Change From Baseline in Percent Body Surface Area (BSA) Involvement
The percentage involvement of psoriasis on each participant's body surface area (BSA) was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 52
Mean Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score
The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail (fn) Ps. This scale is used to evaluate the severity of fn bed Ps and fn matrix Ps by area of involvement in the fn unit. The fn is divided with imaginary horizontal and longitudinal lines into quadrants. Each fn is given a score for fn bed Ps (0 to 4) and fn matrix Ps (0 to 4) depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed and fn matrix Ps in each quadrant. The NAPSI score of a fn is sum of scores in fn bed and fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from 0 to 80 (0 indicates no Ps, 80 indicates worst Ps). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 52
Mean Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS mean change was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 52
Mean Change From Baseline in Palmoplantar PASI (PPASI)
The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 52
Percentage of Participants Achieving an Itch Numeric Rating Scale (Itch NRS) ≥4 Point Reduction From Baseline
The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.
Time frame: Baseline, Week 52
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Total Score of 0 and 1 (DLQI [0,1])
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.
Time frame: Week 52
Change From Baseline in DLQI Total Score
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). LS mean change was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 52
Change From Baseline in Itch NRS Score
The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS mean change from baseline in PSSI was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 52
Change From Baseline in Skin Pain Visual Analog Scale (VAS)
The pain VAS is a participant-administered single-item scale designed to measure Skin pain from Psoriasis using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's skin pain from Psoriasis is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no skin pain) to 100 mm (severe skin pain). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 52
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) VAS
EQ-5D-5L is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0 (no pain) to 100mm VAS (severe pain). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 52
Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough,ss) of Ixekizumab
Trough concentrations at steady state of Ixekizumab were evaluated.
Time frame: Predose, Week 4, 12, 24, 36 and 52 Post dose
Number of Participants With Anti-Ixekizumab Antibodies
Number of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group.
Time frame: Baseline through Week 52
| Milestone | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W | 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort |
|---|---|---|---|---|---|---|
| Started | 310 | 306 | 611 | 9 | 5 | 16 |
| Received at least one dose of study drug | 310 | 306 | 609 | 9 | 5 | 16 |
| Completed | 274 | 268 | 537 | 9 | 4 | 15 |
| Not completed | 36 | 38 | 74 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 11 | 11 | 25 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 13 | 17 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 9 | 7 | 11 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 4 | 5 | 6 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 4 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 4 | 0 | 0 | 0 |
| Withdrew: Site terminated by sponsor | 1 | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Met exclusion criteria and was not dosed | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Due to personal business | 2 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 2 | 0 | 0 | 0 |
| Milestone | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W | 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort |
|---|---|---|---|---|---|---|
| Started | 285 | 283 | 559 | 9 | 4 | 15 |
| Completed | 254 | 244 | 496 | 9 | 4 | 15 |
| Not completed | 31 | 39 | 63 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 12 | 20 | 26 | 0 | 0 | 0 |
| Withdrew: Early terminated but completed follow-up | 12 | 16 | 20 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 2 | 7 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 4 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Subject move out of town | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Subject did not come for visit-802 | 0 | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Labor reasons | 0 | 0 | 1 | 0 | 0 | 0 |
The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.
| Percentage of participants | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1) | 70.6 | 72.5 | 78.6 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants who did not meet the clinical response criteria or had missing data at Week52 were considered non-responders for NRI analysis.
| Percentage of participants | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Percentage of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75) | 79 | 83.7 | 85.9 |
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.
| Percentage of participants | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Percentage of Participants Achieving sPGA (0) | 44.8 | 48.7 | 60.1 |
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| Percentage of participants | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Percentage of Participants Achieving PASI 90 | 65.2 | 73.9 | 79.5 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| Percentage of participants | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Percentage of Participants Achieving PASI 100 | 43.5 | 49.3 | 59.7 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares mean (LSmean) was calculated using Mixed-Effects Model of Repeated Measures (MMRM) analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
| units on a scale | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Change From Baseline in PASI | -18.34 ± 0.22 | -18.95 ± 0.22 | -19.41 ± 0.17 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares mean (LSmean) was calculated using Mixed-Effects Model of Repeated Measures (MMRM) analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
| Percent change | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Percent Improvement in PASI | 91.09 ± 0.89 | 94.24 ± 0.90 | 96.25 ± 0.71 |
The percentage involvement of psoriasis on each participant's body surface area (BSA) was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
| Percent Body Surface Affected | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Mean Change From Baseline in Percent Body Surface Area (BSA) Involvement | -23.93 ± 0.34 | -24.62 ± 0.34 | -25.01 ± 0.27 |
The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail (fn) Ps. This scale is used to evaluate the severity of fn bed Ps and fn matrix Ps by area of involvement in the fn unit. The fn is divided with imaginary horizontal and longitudinal lines into quadrants. Each fn is given a score for fn bed Ps (0 to 4) and fn matrix Ps (0 to 4) depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed and fn matrix Ps in each quadrant. The NAPSI score of a fn is sum of scores in fn bed and fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from 0 to 80 (0 indicates no Ps, 80 indicates worst Ps). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
| units on a scale | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Mean Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score | -19.27 ± 0.81 | -19.87 ± 0.83 | -20.82 ± 0.62 |
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS mean change was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
| units on a scale | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Mean Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score | -18.35 ± 0.31 | -18.73 ± 0.31 | -18.65 ± 0.24 |
The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
| units on a scale | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Mean Change From Baseline in Palmoplantar PASI (PPASI) | -9.55 ± 0.31 | -9.37 ± 0.30 | -9.00 ± 0.26 |
The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.
| Percentage of participants | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Percentage of Participants Achieving an Itch Numeric Rating Scale (Itch NRS) ≥4 Point Reduction From Baseline | 74.0 | 72.3 | 77.2 |
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.
| Percentage of participants | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Total Score of 0 and 1 (DLQI [0,1]) | 66.1 | 70.3 | 74.0 |
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). LS mean change was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
| units on a scale | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Change From Baseline in DLQI Total Score | -9.70 ± 0.21 | -9.97 ± 0.22 | -10.23 ± 0.17 |
The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS mean change from baseline in PSSI was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
| units on a scale | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Change From Baseline in Itch NRS Score | -4.90 ± 0.13 | -5.15 ± 0.13 | -5.33 ± 0.10 |
The pain VAS is a participant-administered single-item scale designed to measure Skin pain from Psoriasis using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's skin pain from Psoriasis is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no skin pain) to 100 mm (severe skin pain). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
| mm | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Change From Baseline in Skin Pain Visual Analog Scale (VAS) | -35.50 ± 0.94 | -36.77 ± 0.96 | -38.07 ± 0.74 |
EQ-5D-5L is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0 (no pain) to 100mm VAS (severe pain). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.
| mm | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) VAS | 11.93 ± 0.94 | 12.47 ± 0.95 | 14.42 ± 0.74 |
Trough concentrations at steady state of Ixekizumab were evaluated.
| microgram per milliliter (µg/mL) | 80 mg Ixekizumab Q4W Continuous | 80 mg Ixekizumab Q4W/Q2W No Step | 80 mg Ixekizumab Q4W/Q2W Step up | 80 mg Ixekizumab Q2W Continuous |
|---|---|---|---|---|
| Week 4 | 3.55 ± 76 | 4.03 ± 72 | 2.78 ± 67 | 7.87 ± 63 |
| Week 12 | 2.72 ± 72 | 2.81 ± 80 | 1.95 ± 70 | 8.23 ± 56 |
| Week 24 | 2.65 ± 73 | 2.71 ± 85 | 3.48 ± 78 | 7.89 ± 66 |
| Week 36 | 2.83 ± 74 | 2.88 ± 73 | 5.76 ± 67 | 7.73 ± 76 |
| Week 52 | 2.43 ± 79 | 2.77 ± 73 | 5.73 ± 68 | 6.96 ± 87 |
Number of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group.
| participants | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W |
|---|---|---|---|
| Number of Participants With Anti-Ixekizumab Antibodies | 71 | 64 | 84 |
Collected over Up to 19 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixekizumab 80 mg Q4W - Treatment Period | 0/310 (0%) | 16/310 (5.2%) | 157/310 (50.6%) |
| 80 mg Ixekizumab Q4W/Q2W - Treatment Period | 0/306 (0%) | 16/306 (5.2%) | 136/306 (44.4%) |
| 80 mg Ixekizumab Q2W - Treatment Period | 0/609 (0%) | 32/609 (5.3%) | 285/609 (46.8%) |
| 80 mg Ixekizumab Q4W - Post-Treatment Period | 0/285 (0%) | 1/285 (0.4%) | 16/285 (5.6%) |
| 80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period | 0/283 (0%) | 2/283 (0.7%) | 20/283 (7.1%) |
| 80 mg Ixekizumab Q2W - Post-Treatment Period | 0/559 (0%) | 7/559 (1.3%) | 40/559 (7.2%) |
| 80 mg Ixekizumab Q4W - Treatment Period ME2 Cohort | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| 80 mg Ixekizumab Q4W/Q2W - Treatment Period ME2 Cohort | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| 80 mg Ixekizumab Q2W - Treatment Period ME2 Cohort | 0/16 (0%) | 0/16 (0%) | 11/16 (68.8%) |
| 80 mg Ixekizumab Q4W - Post-Treatment Period ME2 Cohort | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| 80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period ME2 Cohort | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| 80 mg Ixekizumab Q2W - Post-Treatment Period ME2 Cohort | 0/15 (0%) | 0/15 (0%) | 2/15 (13.3%) |
| Event | Ixekizumab 80 mg Q4W - Treatment Period | 80 mg Ixekizumab Q4W/Q2W - Treatment Period | 80 mg Ixekizumab Q2W - Treatment Period | 80 mg Ixekizumab Q4W - Post-Treatment Period | 80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period | 80 mg Ixekizumab Q2W - Post-Treatment Period | 80 mg Ixekizumab Q4W - Treatment Period ME2 Cohort | 80 mg Ixekizumab Q4W/Q2W - Treatment Period ME2 Cohort | 80 mg Ixekizumab Q2W - Treatment Period ME2 Cohort | 80 mg Ixekizumab Q4W - Post-Treatment Period ME2 Cohort | 80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period ME2 Cohort | 80 mg Ixekizumab Q2W - Post-Treatment Period ME2 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benign bone neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/310 | 0/306 | 0/609 | 0/285 | 0/283 | 0/559 | 0/9 | 1/5 | 0/16 | 0/9 | 0/4 | 0/15 |
| CellulitisInfections and infestations | 2/310 | 2/306 | 1/609 | 0/285 | 0/283 | 0/559 | 0/9 | 0/5 | 0/16 | 0/9 | 0/4 | 0/15 |
| Rib fractureInjury, poisoning and procedural complications | 0/310 | 2/306 | 0/609 | 0/285 | 0/283 | 1/559 | 0/9 | 0/5 | 0/16 | 0/9 | 0/4 | 0/15 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/111 | 0/107 | 0/199 | 0/98 | 0/98 | 1/184 | 0/2 | — | 0/4 | 0/2 | — | 0/4 |
| Tubal rupturePregnancy, puerperium and perinatal conditions | 0/111 | 0/107 | 0/199 | 0/98 | 0/98 | 1/184 | 0/2 | — | 0/4 | 0/2 | — | 0/4 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 1/199 | 0/199 | 0/410 | 0/187 | 0/185 | 0/375 | 0/7 | 0/5 | 0/12 | 0/7 | 0/4 | 0/11 |
| Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/310 | 0/306 | 0/609 | 0/285 | 1/283 | 0/559 | 0/9 | 0/5 | 0/16 | 0/9 | 0/4 | 0/15 |
| Cerebrovascular accidentNervous system disorders | 0/310 | 0/306 | 1/609 | 0/285 | 1/283 | 0/559 | 0/9 | 0/5 | 0/16 | 0/9 | 0/4 | 0/15 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/310 | 0/306 | 0/609 | 1/285 | 0/283 | 0/559 | 0/9 | 0/5 | 0/16 | 0/9 | 0/4 | 0/15 |
| Cardiac failureCardiac disorders | 0/310 | 0/306 | 2/609 | 0/285 | 0/283 | 1/559 | 0/9 | 0/5 | 0/16 | 0/9 | 0/4 | 0/15 |
| Event | Ixekizumab 80 mg Q4W - Treatment Period | 80 mg Ixekizumab Q4W/Q2W - Treatment Period | 80 mg Ixekizumab Q2W - Treatment Period | 80 mg Ixekizumab Q4W - Post-Treatment Period | 80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period | 80 mg Ixekizumab Q2W - Post-Treatment Period | 80 mg Ixekizumab Q4W - Treatment Period ME2 Cohort | 80 mg Ixekizumab Q4W/Q2W - Treatment Period ME2 Cohort | 80 mg Ixekizumab Q2W - Treatment Period ME2 Cohort | 80 mg Ixekizumab Q4W - Post-Treatment Period ME2 Cohort | 80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period ME2 Cohort | 80 mg Ixekizumab Q2W - Post-Treatment Period ME2 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 41/310 | 53/306 | 73/609 | 6/285 | 0/283 | 9/559 | 1/9 | 1/5 | 6/16 | 0/9 | 0/4 | 0/15 |
| Vaginal infectionInfections and infestations | 0/111 | 1/107 | 0/199 | 0/98 | 0/98 | 0/184 | 0/2 | — | 1/4 | 0/2 | — | 0/4 |
| Upper respiratory tract infectionInfections and infestations | 46/310 | 39/306 | 69/609 | 1/285 | 3/283 | 3/559 | 2/9 | 1/5 | 1/16 | 0/9 | 0/4 | 0/15 |
| MumpsInfections and infestations | 0/310 | 0/306 | 0/609 | 0/285 | 0/283 | 0/559 | 0/9 | 1/5 | 0/16 | 0/9 | 0/4 | 0/15 |
| Blood glucose increasedInvestigations | 0/310 | 0/306 | 0/609 | 0/285 | 1/283 | 0/559 | 0/9 | 1/5 | 0/16 | 0/9 | 0/4 | 0/15 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/310 | 5/306 | 25/609 | 2/285 | 1/283 | 4/559 | 0/9 | 1/5 | 1/16 | 0/9 | 0/4 | 0/15 |
| Benign bone neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/310 | 0/306 | 0/609 | 0/285 | 0/283 | 0/559 | 0/9 | 1/5 | 0/16 | 0/9 | 0/4 | 0/15 |
| RashSkin and subcutaneous tissue disorders | 3/310 | 3/306 | 4/609 | 0/285 | 0/283 | 3/559 | 0/9 | 1/5 | 0/16 | 0/9 | 0/4 | 0/15 |
| Injection site erythemaGeneral disorders | 4/310 | 3/306 | 18/609 | 0/285 | 0/283 | 0/559 | 0/9 | 0/5 | 2/16 | 0/9 | 0/4 | 0/15 |
| Injection site oedemaGeneral disorders | 1/310 | 0/306 | 1/609 | 0/285 | 0/283 | 0/559 | 0/9 | 0/5 | 2/16 | 0/9 | 0/4 | 0/15 |
All randomized participants.
| Age, Continuous(years) | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W | 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort | Total |
|---|---|---|---|---|---|---|---|
| Mean | 47.4 ± 13.50 | 45.9 ± 12.85 | 49.0 ± 13.61 | 40.0 ± 9.62 | 46.0 ± 13.17 | 46.1 ± 13.05 | 47.8 ± 13.45 |
| Sex: Female, Male(Participants) | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W | 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort | Total |
|---|---|---|---|---|---|---|---|
| Female | 111 | 107 | 199 | 2 | 0 | 4 | 423 |
| Male | 199 | 199 | 412 | 7 | 5 | 12 | 834 |
| Ethnicity (NIH/OMB)(Participants) | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W | 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 59 | 55 | 111 | 0 | 0 | 0 | 225 |
| Not Hispanic or Latino | 243 | 244 | 489 | 9 | 5 | 16 | 1006 |
| Unknown or Not Reported | 8 | 7 | 11 | 0 | 0 | 0 | 26 |
| Race (NIH/OMB)(Participants) | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W | 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 11 | 12 | 23 | 0 | 0 | 0 | 46 |
| Asian | 31 | 32 | 64 | 9 | 5 | 16 | 157 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 4 | 0 | 0 | 0 | 4 |
| Black or African American | 14 | 8 | 22 | 0 | 0 | 0 | 44 |
| White | 251 | 253 | 486 | 0 | 0 | 0 | 990 |
| More than one race | 3 | 1 | 12 | 0 | 0 | 0 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 80 mg Ixekizumab Q4W | 80 mg Ixekizumab Q4W/Q2W | 80 mg Ixekizumab Q2W | 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort | 80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort | Total |
|---|---|---|---|---|---|---|---|
| Puerto Rico | 14 | 16 | 29 | 0 | 0 | 0 | 59 |
| Argentina | 9 | 9 | 19 | 0 | 0 | 0 | 37 |
| Romania | 5 | 5 | 9 | 0 | 0 | 0 | 19 |
| Hungary | 11 | 10 | 23 | 0 | 0 | 0 | 44 |
| United States | 119 | 118 | 238 | 0 | 0 | 0 | 475 |
| Czechia | 3 | 3 | 8 | 0 | 0 | 0 | 14 |
| Japan | 5 | 2 | 9 | 0 | 0 | 0 | 16 |
| Canada | 49 | 49 | 99 | 0 | 0 | 0 | 197 |
| South Korea | 11 | 12 | 22 | 9 | 5 | 16 | 75 |
| Taiwan | 5 | 6 | 9 | 0 | 0 | 0 | 20 |
| Poland | 43 | 43 | 83 | 0 | 0 | 0 | 169 |
| Mexico | 10 | 8 | 17 | 0 | 0 | 0 | 35 |
| Australia | 14 | 14 | 28 | 0 | 0 | 0 | 56 |
| Germany | 12 | 11 | 18 | 0 | 0 | 0 | 41 |
Showing the first 100 of 125 sites across 14 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Aug 2015, a primary completion of Nov 2016 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2018, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab